Robert Kleiman
Podiatrist · Calexico, CANPI 1639132640
Payments from drug & device makers
What this record shows
This record is dominated by other: $912,215 of the $912,818 with a category attached, or 99.9%. Convatec Inc. accounts for 99.9% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $912,215, more than ten times the $201 reported in 2019. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $11,132 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Convatec Inc.$912K
- Smith+Nephew$477
- Angiodynamics, Inc.$63
- Misonix Inc$24
- Novo Nordisk$21
- Merck$18
What the payments were for
- Food & beverage$6030%
- Other$912,215100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Convatec Inc. | 56 | $912,215 |
| Smith+Nephew | 22 | $477 |
| Angiodynamics, Inc. | 1 | $63 |
| Misonix Inc | 1 | $24 |
| Novo Nordisk | 1 | $21 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InnovaMatrix AC$912,215
- REGRANEX$122
How this compares
$912,818 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 884 | $36,134 |
| Betamethasone Dipropionate | 263 | $24,274 |
| Clotrimazole | 646 | $21,927 |
| Diclofenac Sodium | 27 | $7,147 |
| Mupirocin | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Calexico
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Bruce LawrenceOceanside$810K
- David ArmstrongLos Angeles$695K
- Philip WrotslavskyPoway$269K
- Travis WestermeyerEncinitas$158K
- Adrienne EstesPomona$129K
- Ronald LiebermanEncinitas$109K
- Matthew DoyleMountain View$92K
- Charles AnanianLos Angeles$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.